Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02405260 · ClinicalTrials.gov registry record · Phase 2
Add Glucokinase Activator to Target A1c
A Phase 2 study of Diabetes Mellitus, Type 2, sponsored by vTv Therapeutics.
- Completed
- Registry status
- Phase 2
- Development phase
- 190
- Enrollment target
- 20
- Study locations
NCT02405260: Completed Phase 2 study of Diabetes Mellitus, Type 2, sponsored by vTv Therapeutics.
NCT02405260 is a Phase 2 study of Diabetes Mellitus, Type 2 that has completed, run by vTv Therapeutics. The registered enrollment target is 190 participants, below the 4,485-participant average among 348 other Diabetes Mellitus, Type 2 trials with a reported enrollment target (96% lower). The trial reports 20 study locations across 13 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02405260, a Phase 2 study of Diabetes Mellitus, Type 2, has completed, sponsored by vTv Therapeutics.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 190 participants
- Enrollment target
- 20
- Study locations
Study Summary
This trial is a multi-center, adaptive, randomized, double-blind, placebo- and active- controlled, parallel group, Phase 2 study in subjects with T2DM to evaluate the effect of TTP399 on HbA1c following administration for 6 months.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Sitagliptin 100 mg
- DRUG TTP399 400 mg
- DRUG TTP399 800 mg
Study Locations (20)
California
- - Canoga Park
- - Huntington Park
- - Los Angeles
- - West Hills
Texas
- - San Antonio
- - San Antonio
- - Schertz
Arizona
- - Mesa
- - Tuscon
Colorado
- - Centennial
- - Littleton
Connecticut
- - Waterbury
Florida
- - West Palm Beach
Illinois
- - Gurnee
Indiana
- - Evansville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 190 participants |
| Start Date | 2015-03 |
| Est. Completion | 2016-09 |
| Phase | Phase 2 |
What the finished NCT02405260 record still lists
NCT02405260 is an interventional study that assigns participants to a tested intervention. The registered 190 participants enrollment target is mid-sized for trials with a published cap, below the 4,485-participant average among 348 other Diabetes Mellitus, Type 2 trials with a reported enrollment target (96% lower).
The record links to 1 condition, with Diabetes Mellitus, Type 2 appearing as the primary indexed condition, and to 4 interventions - of which Placebo is the first listed.
NCT02405260 names 20 study sites across 13 states, led by California, Texas, Arizona.
Frequently Asked Questions
What is clinical trial NCT02405260 about?
NCT02405260 is a clinical study titled "Add Glucokinase Activator to Target A1c". This trial is a multi-center, adaptive, randomized, double-blind, placebo- and active- controlled, parallel group, Phase 2 study in subjects with T2DM to evaluate the effect of TTP399 on HbA1c following administration for 6 months.
What is the current status of trial NCT02405260?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 190 participants. The study started on 2015-03. Estimated completion is 2016-09.
What conditions does trial NCT02405260 study?
This clinical trial studies the following conditions: Diabetes Mellitus, Type 2.
What interventions are being tested in trial NCT02405260?
The interventions under investigation include: Placebo (DRUG), Sitagliptin 100 mg (DRUG), TTP399 400 mg (DRUG), TTP399 800 mg (DRUG).
Who is sponsoring clinical trial NCT02405260?
This trial is sponsored by vTv Therapeutics, which has 13 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02405260 being conducted?
This trial has 20 study locations across Arizona, California, Colorado, Connecticut, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Diabetes Mellitus, Type 2
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT02405260's enrollment target sits among peer trials
190 159th of 348 higher than 190 of 348 other Diabetes Mellitus, Type 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Diabetes Mellitus, Type 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
DETERMINE: Detemir vs NPH
RECRUITING · Phase 2
-
MANAGe-DM: Novel Nurse Case Management to Improve Diabetes Outcomes in Formerly Incarcerated Black Men
RECRUITING · Phase 2
-
A Study of Macupatide (LY3532226) and Eloralintide (LY3841136), Alone or in Combination, in Adults With Obesity or Overweight and With Type 2 Diabetes
RECRUITING · Phase 2
-
A Study of LY3938577 in Participants With Type 2 Diabetes Previously Treated With Basal Insulin
RECRUITING · Phase 2
-
A Research Study to Investigate the Effects of CagriSema Compared to Placebo in People With Type 2 Diabetes and Painful Diabetic Peripheral Neuropathy
ACTIVE NOT RECRUITING · Phase 2
-
Addressing Basic Needs to Improve Diabetes Outcomes in Medicaid Beneficiaries
ACTIVE NOT RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03257033 · 190 participants · Phase 3
Intra-arterial Gemcitabine vs. IV Gemcitabine and Nab-Paclitaxel Following Radiotherapy for LAPC
- NCT03642028 · 190 participants · Phase 4
Suvorexant: A Dual Orexin Receptor Antagonist for Treating Sleep Disturbance in Posttraumatic Stress
- NCT04015609 · 190 participants · NA
Psychotherapy Intervention for Latinos With Advanced Cancer
- NCT04284397 · 190 participants · Early Phase 1
Identification of Critical Thermal Environments for Aged Adults
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia